Provided by Tiger Trade Technology Pte. Ltd.

iShares Health Innovation Active ETF

34.34
+0.68772.04%
Post-market: 33.65-0.6880-2.00%16:04 EDT
Volume:2K
Turnover:54.52K
Market Cap:13.74M
PE:- -
High:34.34
Open:33.65
Low:33.65
Close:33.65
52wk High:34.98
52wk Low:27.25
Shares:400.00K
Float Shares:400.00K
Volume Ratio:0.76
T/O Rate:0.40%
Dividend:0.08
Dividend Rate:0.24%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Johnson & Johnson (JNJ) Faces Fresh Patent Lawsuit Over Cardiology Device

Simply Wall St.
·
21 mins ago

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
19 hours ago

Moderna Inc. Stock Advances 14.2%, Outperforms Peers

Dow Jones
·
19 hours ago

U.S. Stocks on the MOVE -VF Corp, Biogen, AbbVie

Reuters
·
22 hours ago

Sector Update: Healthcare

MT Newswires Live
·
22 hours ago

Top Midday Stories: Delta Shares Fall After Q3 EPS, Revenue Misses; Apple Reportedly Cuts iPhone 18 Pro Component Orders Due to Soft Demand

MT Newswires Live
·
23 hours ago

UBS Lifts Biogen PT on Late-Stage Pipeline Catalysts; Shares Rise

Reuters
·
23 hours ago

Pacira Biosciences' Acquisition by Viatris Unlikely to See Superior Bid, RBC Says

MT Newswires Live
·
Yesterday

Looking for Dividend Aristocrats? These 3 Healthcare Stocks Deserve a Closer Look

TIPRANKS
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Yesterday

Merck & Company (MRK) Receives a Buy from UBS

TIPRANKS
·
Yesterday

GH Research to Present TRD and Bipolar Trial Data at ECNP 2026

TIPRANKS
·
Yesterday

Johnson & Johnson reports new two-year results from Phase 3 ICONIC-LEAD study

TIPRANKS
·
Yesterday

Teva announces FDA approval for Weltruza

TIPRANKS
·
Yesterday

J&J Says Phase 3 Iconic-LEAD Trial Shows Icotyde Sustains Plaque Psoriasis Clearance Through 2 Years

Reuters
·
Yesterday

J&J - at Week 112, 72% Achieve Pasi 90, 70% Achieve Iga 0/1 with Icotyde

THOMSON REUTERS
·
Yesterday

J&J - no New Safety Signals Identified for Icotyde Through Week 112

THOMSON REUTERS
·
Yesterday

New Johnson & Johnson Icotyde® (Icotrokinra) Long-Term Data Demonstrate Robust 2-Year Results in the Treatment of Adults and Adolescents with Plaque Psoriasis

THOMSON REUTERS
·
Yesterday

Merck price target lowered to $163 from $166 at BofA

TIPRANKS
·
Yesterday

MedPal AI Sets October General Meeting as It Advances AI-Driven Health Platform

TIPRANKS
·
Yesterday